If your area shows an “A(H5) detected” wastewater result, it’s a community monitoring signal—not proof that anyone in your household is infected. Learn what the dashboard can and can’t tell you, and when symptoms after relevant exposure should prompt medical evaluation.
If you call or text 988 and your local crisis option can’t take your contact, the system is designed to route you to a national backup. Wait times can still vary by call/text/chat method and local demand—so if one path doesn’t connect, trying another 988 method can help you reach a counselor faster.
New HRSA-backed U.S. cervical cancer screening guidance adds a patient-collected (at-home) option for high-risk HPV testing for average-risk adults ages 30 to 65. The preferred screening interval is every 5 years, and abnormal results may require additional follow-up tests to complete screening.
CMS’s proposed CY 2027 Hospital OPPS/ASC rule would adjust Medicare hospital outpatient payments for certain 340B-acquired drugs, change how some outpatient imaging is paid (including rural Sole Community Hospital exemptions), and continue the phase-out of the Inpatient Only (IPO) list. CMS also issued an RFI to improve hospital price-transparency data. The proposal is not final; comments are due August 31, 2026.
On June 10, 2026, FDA approved updates to the OTC weight-loss drug alli (orlistat 60 mg) label to highlight a rare risk of acute kidney injury and kidney stones. The label advises people who have ever had kidney disease or kidney stones to ask a health care provider first, and to stop using alli and contact a doctor if specific kidney-related symptoms appear.
If you may have been exposed to mpox, JYNNEOS post-exposure prophylaxis works best when started within 4 days (and may still help if given up to 14 days). If you develop a new, unusual rash after a relevant exposure window, contact a clinician promptly to ask about mpox PCR testing.
A May 29, 2026 executive order directs CDC and ACIP to review how childhood vaccines are organized and to update guidance using “best practices”—while aiming to preserve access to vaccines already available in the U.S. Here’s what families and schools can do today to stay on track, understand “core” versus shared decision-making vaccines, and reduce appointment and coverage confusion.
If you have a Hintermann Series H3 total ankle replacement—or are considering one—FDA says the long-term risk of device failure and possible revision surgery is higher than expected. FDA advises keeping follow-ups and contacting your health care provider promptly if specific new or worsening symptoms appear.
A July 1, 2026 randomized trial (CICERO) tested goal-oriented cognitive rehabilitation for long COVID “brain fog.” It improved participants’ personalized functional goal attainment at 3 months and maintained the advantage at 6 months. But the trial did not show clear improvement in fatigue/post-exertional malaise (PEM) or several other symptom domains.
CDC says cyclosporiasis cases have increased in the U.S. Prolonged watery diarrhea can last weeks, and routine stool testing may miss Cyclospora. Here’s what to ask about Cyclospora-specific testing, what results can mean, and what CDC says about treatment with TMP-SMX and key safety cautions.
CMS enforcement of updated hospital price transparency requirements starts April 1, 2026. Here’s what hospitals must post, what “standard charges” mean, what they don’t tell you about your bill, and how to use the files for scheduled care.
If you ate the recalled Clover Hill Dairy soft ricotta/requesón, CDC says listeria symptoms can start the same day or take weeks—up to 10 weeks. Pregnancy and other high-risk groups should call right away if symptoms appear.
A CDC snapshot (as of May 23, 2026) shows many more children reported getting a seasonal flu vaccine than a 2025–26 COVID-19 vaccine. Here’s a calm, step-by-step catch-up plan and how families can use the VFC program if cost is a barrier.
On June 12, 2026, the FDA approved an ODACTRA (house dust mite) sublingual immunotherapy label update adding “dizziness” and “rash” to postmarketing adverse-reaction wording. Here’s what that means for allergy symptom monitoring, who should not use ODACTRA, and when to stop and get urgent help.
FDA’s VRBPAC reviewed investigational Moderna’s mRNA flu vaccine candidate (mFlusiva/mRNA-1010) for adults 50+. The Phase 3 signal showed a relative efficacy benefit versus a standard-dose comparator, but short-term reactions were more common than in the comparator. Key uncertainties—like limited data in the frail/high-risk older adults and limited duration-of-protection evidence—remain. CDC guidance is still to get an approved flu vaccine now rather than waiting.
CMS issued an interim final rule for Medicaid “community engagement” (80 hours/month) that states generally must start by Jan. 1, 2027. Here’s who is subject, what can count toward the hours, which exemptions—including medical frailty—may apply, and what to do if your state can’t verify compliance.
FDA posted a May 26, 2026 voluntary medical device correction for certain Omnipod 5, Omnipod DASH, and Omnipod Eros (insulin management system) pod lots due to a manufacturing issue that could cause insulin under-delivery. Here’s how to check your pod lot and when DKA warning signs mean you need emergency care.
EPA updated its home asthma-trigger guidance on July 6, 2026. Use this practical room-by-room routine to reduce exposure to wood smoke, dust mites, mold/moisture, pets, and irritant chemicals—plus clear danger signs for when to get emergency help.
Feeling fine doesn’t rule out oral cancer risk. This explainer explains what “oral cancer screening” means during a dental visit and what the 2026 ADA living guideline says about brush cytology—especially why a negative result doesn’t replace biopsy when an abnormal area is found or persists.
CMS says enforcement of updated hospital price-transparency requirements starts April 1, 2026. For rural patients, CMS’s enforcement-activity dataset can help you see where compliance reviews happened and what CMS did—but it won’t tell you your exact out-of-pocket bill.
Starting July 1, 2026, eligible Medicare Part D beneficiaries can access certain GLP-1 weight-loss medicines through the Medicare GLP-1 Bridge at a predictable $50/month copay, through December 31, 2027. Eligibility depends on age, BMI/health conditions, and whether someone already gets a GLP-1 through their Part D plan.
FDA warns that the TRUE METRIX “E-5” message can mean either a very high blood sugar event (over 600 mg/dL) or a test-strip error. Don’t guess—switch to an alternative glucose-testing method if possible, keep testing until you have an alternative, and contact your clinician right away if E-5 shows up with symptoms of low or high blood sugar.
End of content
End of content